Key facts
- Brazilian customs agents seized over 2,500 vials of weight-loss drug ingredients smuggled from Paraguay.
- Health officials are concerned about a potential public health crisis due to a booming black market for weight-loss medications.
- Over 3,600 complications and 83 deaths are under investigation in Brazil, linked to weight-loss drugs.
- An estimated 51% of Brazil's weight-loss drug sales are expected to come from smuggled or custom-mixed products.
- Brazil's GLP-1 usage rate is 5.5%, higher than the global average.
- Authorities are approving cheaper, authorized alternatives to steer consumers away from illegal imports.
Brazilian authorities are confronting a burgeoning black market for weight-loss drugs, fueled by high demand and limited purchasing power. Customs agents have intercepted large quantities of smuggled medications, including tirzepatide (Mounjaro) and semaglutide (Wegovy), hidden in various unconventional ways, such as mixed within dulce de leche or concealed in vehicle parts.
Health officials express grave concerns about a potential public health crisis, citing over 3,600 reported complications and 83 deaths under investigation linked to these drugs. It is estimated that 51% of Brazil's $7 billion weight-loss drug market this year will stem from custom-mixed or smuggled products, often sourced from Paraguay where patent laws are more lenient. Consumers, driven by a beauty-conscious culture, are willing to risk using unvetted medications, with some purchasing Paraguayan drugs like T.G. despite lacking official approval.
Manufacturers like Eli Lilly and Novo Nordisk acknowledge the issue, stating they support efforts to combat the illegal market and are working to improve the affordability of their regulated treatments. The proliferation of these drugs has cemented Brazil's status as a global beauty hub. Brazil's GLP-1 usage rate stands at 5.5%, surpassing the global average, and seizures of illegal drugs have surged dramatically.
Experts warn of significant health risks associated with unregulated weight-loss treatments, including poor storage, heat exposure, acute pancreatitis, hypoglycemia, and digestive issues that can lead to aspiration and pneumonia. The widespread availability of these drugs through unofficial channels, from pharmacies to street markets, has led to severe complications for some users, with one doctor describing the situation as "drug trafficking."
In response, Brazilian authorities are approving cheaper, authorized weight-loss alternatives, hoping to divert demand from the illegal market. Anvisa has approved domestic alternatives like Ozivy, priced significantly lower than smuggled options, aiming to provide a safer and more accessible choice for consumers.